At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
SAR443765 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma
In Brief
A Phase 1 clinical trial evaluating SAR443765, Placebo, and 1 other intervention for Asthma. Completed, enrolled 36 participants across 2 sites in 2 countries.
Detailed Summary
This is a 3-part, parallel group treatment, Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics after sequential single and multiple ascending doses of SAR443765 in healthy adult participants, and after a single dose of SAR443765 in participants with mild-to-moderate asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartJun 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedMay 9, 2022
Enrollment StartJun 8, 2022
Primary CompletionFeb 24, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.1 years ago
Interventions
SAR443765drug
solution for injection
Placebodrug
solution for injection
Salbutamol or levosalbutamoldrug
metered dose inhaler